FAIRFIELD, N.J., Jan. 4 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that the Company has established A. Aarons, Inc., a subsidiary of Bradley Pharmaceuticals, to market, on a select basis, authorized generic versions of therapies provided by Bradley’s Doak Dermatologics and Kenwood Therapeutics operating units. A. Aarons will be headed by William Renzo, Vice President, Trade/Managed Care Relations for Bradley Pharmaceuticals.
As the multi-source arm for Bradley Pharmaceuticals, A. Aarons will attempt to maximize revenue by capturing current and potential lost revenue from Doak and Kenwood brands that face current or potential generic competition. The long-term goal of A. Aarons is to capture a meaningful share of the generic markets for Doak and Kenwood brands that face generic competition. Bradley anticipates that A. Aarons will commence operations during the First Quarter of 2006.
President and CEO, Daniel Glassman, stated, “The Bradley Management Team believes that the establishment of A. Aarons as a Bradley subsidiary reflects the Company’s ongoing commitment to life cycle management. Bradley is entering this venture optimistically, with realistic expectations and appropriate management to achieve the Company’s established goals.”
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and 38 international markets. Bradley’s success is based on the strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic brands, Enhances these brands with line extensions and improved formulations and Grows the products through promotion, advertising and selling activities to optimize life cycle management. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical therapies for dermatology and podiatry, and Kenwood Therapeutics, providing gastroenterology, respiratory and other internal medicine brands.
Important announcement:
Daniel Glassman will present at the Raymond James & Associates 27th Annual Institutional Investors Conference, Hyatt Regency Grand Cypress in Orlando, FL, March 5-8th, 2006.
Daniel Glassman will present at the Banc of America Securities LLC, Health Care Conference 2006, to be held at The Four Seasons Hotel in Las Vegas, NV, May 16-18th, 2006.
Please visit Bradley Pharmaceuticals web site at: http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the symbol BDY
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by Bradley of new products and market acceptance of Bradley’s products. Forward-looking statements are based on Bradley’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond Bradley’s control. These risks and uncertainties include Bradley’s ability to compete in the generic marketplace; ability to comply with the restrictive covenants under its credit facility; ability to access the capital markets on attractive terms or at all; ability to favorably resolve the pending SEC informal inquiry and file required financial statements with the SEC in accordance with the Company’s announced timetable, maintain sales of its products, successfully acquire, develop, integrate, or sell new products or effectively react to other risks and uncertainties described from time to time in Bradley’s SEC filings, such as fluctuation of quarterly financial results, estimation of product returns, chargebacks, rebates and allowances, concentration of customers, reliance on third party manufacturers and suppliers, litigation or other proceedings (including the pending class action lawsuits), government regulation and stock price volatility. Further, Bradley cannot accurately predict the impact on its business of the approval, introduction, or expansion by competitors of generic or therapeutically equivalent or comparable versions of Bradley’s products or of any other competing products. In addition, actual results may differ materially from those projected. Bradley undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Bradley Pharmaceuticals, Inc.
CONTACT: Anthony Griffo, Investor Relations of Bradley Pharmaceuticals,Inc., +1-973-882-1505, ext. 313
Web site: http://www.bradpharm.com/
